Adial Pharmaceuticals Stock (NASDAQ:ADIL)
Previous Close
$1.09
52W Range
$0.77 - $4.17
50D Avg
$1.04
200D Avg
$1.26
Market Cap
$7.24M
Avg Vol (3M)
$172.08K
Beta
1.30
Div Yield
-
ADIL Company Profile
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.
ADIL Performance
Peer Comparison
| Ticker | Company |
|---|---|
| HOTH | Hoth Therapeutics, Inc. |
| RVPH | Reviva Pharmaceuticals Holdings, Inc. |
| BPTH | Bio-Path Holdings, Inc. |
| KTTA | Pasithea Therapeutics Corp. |
| ADTX | Aditxt, Inc. |
| REVB | Revelation Biosciences, Inc. |
| RNAZ | TransCode Therapeutics, Inc. |
| TNXP | Tonix Pharmaceuticals Holding Corp. |
| VRAX | Virax Biolabs Group Limited |
| RNXT | RenovoRx, Inc. |
| NRBO | NeuroBo Pharmaceuticals, Inc. |
| ATXI | Avenue Therapeutics, Inc. |
| BNTC | Benitec Biopharma Inc. |
| ALRN | Aileron Therapeutics, Inc. |